New medicine to help highly sensitised children receive kidney transplants
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new medicine called imlifidase that quickly removes harmful antibodies from the blood. It is given to children before a kidney transplant to make the donated kidney more likely to be accepted, especially when standard desensitisation methods have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- The child must be between 1 and 17 years old and waiting for a kidney transplant.
- The child must have a very high level of antibodies (80% or more) that make it hard to find a matching kidney.
- Previous attempts to lower these antibodies (like plasmapheresis or IVIg) have not worked, or doctors think they would be too difficult.
- A test shows the donor kidney would likely be rejected (positive crossmatch) unless treated.
- The child must be healthy enough for transplant surgery and must not have had certain infections or treatments in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug imlifidase for people who are highly sensitized (have many antibodies) and waiting for a kidney transplant. It aims to help them receive a kidney from a deceased donor even if they have a positive crossmatch (a test that would normally stop the transplant).
This study tests whether a special immune-resetting treatment can help patients who have developed too many antibodies against donor kidneys get access to a compatible kidney transplant. The treatment uses chemotherapy and stem cell transplantation to 'reset' your immune system so it stops rejecting potential donor kidneys.
This trial tests a new treatment using your own immune cells, called tolerogenic dendritic cells, to help your body accept a kidney transplant. It is designed for people who are highly sensitized and have a very hard time finding a matching donor kidney.
This trial tests a new drug, OM336, to reduce antibodies that make it hard to find a matching kidney for transplant. It may help people who have been waiting a long time for a kidney or who have a living donor but their antibodies attack the donor kidney.
This trial tests a drug called BiTE to reduce high antibody levels (cPRA ≥90%) in people waiting for a kidney transplant. If it works, it might help you become eligible for a transplant sooner.
This trial tests if a special stem cell treatment (using your own stem cells) can reset your immune system so you can accept a kidney from a deceased donor, even if you have very high antibody levels that make it hard to find a match. It's for people who have been waiting a long time and haven't had a transplant offer.
Hear when a new Kidney Transplantation in Highly Sensitized Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.